ME00977B - Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta - Google Patents

Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta

Info

Publication number
ME00977B
ME00977B MEP-2010-24A MEP2410A ME00977B ME 00977 B ME00977 B ME 00977B ME P2410 A MEP2410 A ME P2410A ME 00977 B ME00977 B ME 00977B
Authority
ME
Montenegro
Prior art keywords
pain
human
growth factor
nerve growth
ngf
Prior art date
Application number
MEP-2010-24A
Other languages
English (en)
Inventor
Joel C Reinhardt
Lynn Macdonald
Richard Torres
Marc R Morra
Joel H Martin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ME00977B publication Critical patent/ME00977B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Humano antitelo ili antigen-vezujući fragment antitela, koji specifično vezuje humani nervni faktor rasta (NGF), sa KD od 5 pM ili manje, bez unakrsnog reagovanja sa neurotrofinom-3 (NT-3), i vezuje humani NGF sa KD od oko 2 do oko 10-puta većom u odnosu na onu kojom antitelo ili fragment vezuje NGF pacova i miša. Antitela su korisna u tretmanu bola, uključujući inflamatorni bol, bol nakon operativne incizije, neuropatski bol, bol frakture, bol osteoporozne frakture, post-herpesnu neuralgiju, osteoartritis, reumatoidni artritis, kancerski bol, bol koji proističe iz opekotina, bol kod zglobnog gihta, kao i bolesti, kao što su: hepatocelularni karcinom, rak dojke i ciroza jetre.
MEP-2010-24A 2007-08-10 2008-08-08 Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta ME00977B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96422407P 2007-08-10 2007-08-10
US99452607P 2007-09-20 2007-09-20
US6286008P 2008-01-28 2008-01-28
US7925908P 2008-07-09 2008-07-09
PCT/US2008/072561 WO2009023540A1 (en) 2007-08-10 2008-08-08 High affinity human antibodies to human nerve growth factor

Publications (1)

Publication Number Publication Date
ME00977B true ME00977B (me) 2012-06-20

Family

ID=39951432

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2010-24A ME00977B (me) 2007-08-10 2008-08-08 Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta
MEP-2014-642A ME02239B (me) 2007-08-10 2008-08-08 Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2014-642A ME02239B (me) 2007-08-10 2008-08-08 Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta

Country Status (32)

Country Link
US (3) US7988967B2 (me)
EP (2) EP2187964B1 (me)
JP (1) JP5632744B2 (me)
KR (2) KR101709488B1 (me)
CN (1) CN101827609B (me)
AU (1) AU2008287037B2 (me)
BR (1) BRPI0815370B8 (me)
CA (1) CA2695997C (me)
CO (1) CO6261383A2 (me)
CR (1) CR11298A (me)
CY (1) CY1116072T1 (me)
DK (1) DK2187964T3 (me)
DO (1) DOP2010000054A (me)
EC (1) ECSP10010029A (me)
ES (1) ES2517872T3 (me)
HK (1) HK1144379A1 (me)
HR (1) HRP20141025T1 (me)
IL (1) IL203558A (me)
MA (1) MA31695B1 (me)
ME (2) ME00977B (me)
MX (1) MX2010001395A (me)
MY (2) MY153781A (me)
NI (1) NI201000021A (me)
NZ (1) NZ583200A (me)
PL (1) PL2187964T3 (me)
PT (1) PT2187964E (me)
RS (1) RS53661B1 (me)
RU (1) RU2473564C2 (me)
SI (1) SI2187964T1 (me)
TN (1) TN2010000059A1 (me)
WO (1) WO2009023540A1 (me)
ZA (1) ZA201000725B (me)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
SI2263692T1 (sl) * 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ME00977B (me) 2007-08-10 2012-06-20 Regeneron Pharma Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
JP5642683B2 (ja) 2008-09-19 2014-12-17 ファイザー・インク 安定な液体抗体配合物
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
SG196855A1 (en) 2008-10-22 2014-02-13 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AU2016202118B2 (en) * 2009-03-20 2017-10-26 Amgen Inc. Carrier immunoglobulins and uses thereof
UY32608A (es) * 2009-05-04 2010-12-31 Pangenetics 110 B V Anticuerpos contra el factor de crecimiento nervioso (ngf) con una estabilidad in vivo mejorada
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
NO2792236T3 (me) 2009-07-08 2018-04-14
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
UA108991C2 (uk) * 2009-10-23 2015-07-10 Милленниум Фармасьютикалз, Инк. Молекула антитіла до gcc і пов'язані композиції та способи лікування раку
SG10201504808XA (en) * 2010-03-17 2015-07-30 Abbott Res Bv Anti-Nerve Growth Factor (NGF) Antibody Compositions
US8933084B2 (en) 2010-05-20 2015-01-13 Array Biopharma Inc. Macrocyclic compounds as Trk kinase inhibitors
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
HUE058226T2 (hu) 2010-08-19 2022-07-28 Zoetis Belgium S A NGF elleni antitestek és alkalmazásuk
AU2015258217A1 (en) * 2010-08-19 2015-12-03 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2821515A1 (en) 2010-12-01 2012-06-07 Alder Biopharmaceuticals, Inc. Anti-ngf compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
CN102198272B (zh) * 2011-05-27 2013-01-02 北京中科拜克生物技术有限公司 一种促进骨折愈合的药物组合物
SI2743348T1 (en) 2011-08-11 2018-04-30 Astellas Pharma Inc. NEW ANTI-HUMAN NUFF PROTIVAL
CN107056936B (zh) 2011-09-19 2021-09-03 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9000129B2 (en) 2012-04-27 2015-04-07 Millennium Pharmaceuticals, Inc. Anti-GCC antibody molecules and methods for use of same
JO3820B1 (ar) * 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
AU2013271564A1 (en) * 2012-06-06 2014-12-04 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
BR112015003032B1 (pt) 2012-08-13 2023-03-28 Genentech, Inc Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2015027154A2 (en) 2013-08-23 2015-02-26 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
US9353189B2 (en) 2014-01-24 2016-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
DK3699181T3 (da) 2014-11-16 2023-03-20 Array Biopharma Inc Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
DK3221359T3 (da) 2014-11-17 2020-06-22 Regeneron Pharma Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
WO2016127149A2 (en) 2015-02-06 2016-08-11 Cell Idx, Inc. Antigen-coupled immunoreagents
CN104777311B (zh) * 2015-02-12 2016-08-17 北京华安科创生物技术有限公司 抗人神经生长因子hNGF的单克隆抗体及hNGF的定量检测试剂盒
CN104774265B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
CN104910274B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
MX2017014911A (es) 2015-05-22 2018-03-23 Astellas Pharma Inc Fragmento fab de anticuerpo ngf anti-humano novedoso.
KR20180035911A (ko) * 2015-08-13 2018-04-06 메르크 파텐트 게엠베하 Fgf-18 화합물을 포함하는 조합 조성물
WO2017075107A1 (en) 2015-10-26 2017-05-04 Nanda Nisha Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3439662B1 (en) 2016-04-04 2024-07-24 Loxo Oncology, Inc. Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN107286233B (zh) * 2016-04-13 2020-11-06 舒泰神（北京）生物制药股份有限公司 低痛神经生长因子突变体
SI3800189T1 (sl) 2016-05-18 2023-11-30 Loxo Oncology, Inc. Priprava (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo (1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
US20190265235A1 (en) * 2016-07-18 2019-08-29 Cell Idx, Inc. Reagent compounds, compositions, kits, and methods for amplified assays
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US10736961B2 (en) * 2016-11-29 2020-08-11 Regeneron Pharmaceuticals, Inc. Method of averting opioid addiction
EP3558347A1 (en) 2016-12-22 2019-10-30 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN114751982B (zh) * 2017-12-15 2023-06-23 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途
CN108059676B (zh) * 2017-12-28 2020-07-31 未名生物医药有限公司 一种抗人神经生长因子scFv抗体及制备方法
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
WO2019200326A1 (en) 2018-04-13 2019-10-17 Rarecyte, Inc. Kits for labeling of biomarkers and methods of using the same
CN108623687A (zh) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
EP3795176A4 (en) 2018-05-15 2022-01-12 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
JP7460598B2 (ja) 2018-08-10 2024-04-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 膝および／または股関節痛の安全で効果的な処置用の医薬組成物
WO2020047389A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
JP2020117502A (ja) 2019-01-28 2020-08-06 ファイザー・インク 変形性関節症の徴候および症状を処置する方法
JP2020143045A (ja) 2019-02-18 2020-09-10 ファイザー・インク 慢性腰背部疼痛の処置の方法
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
WO2020248942A1 (zh) * 2019-06-10 2020-12-17 山东博安生物技术有限公司 抗β-NGF纳米抗体及其应用
CA3163270A1 (fr) * 2019-12-31 2021-07-08 Rene Azoulai Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires
CN117050175B (zh) * 2020-04-17 2024-07-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN117003868B (zh) * 2020-04-17 2024-04-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
WO2021238886A1 (en) * 2020-05-27 2021-12-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Ampsource Biopharma Shanghai Inc. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
CN112625128B (zh) * 2020-08-06 2022-11-08 熙源安健医药（上海）有限公司 抗ngf抗体及其抗原结合片段、其制备方法和应用
AU2021350424A1 (en) 2020-09-28 2023-06-01 Medimmune Limited Compounds and methods for treating pain
CN114470189B (zh) * 2020-11-12 2024-01-16 达石药业(广东)有限公司 Ngf抗体在cipn性疼痛中的应用
WO2022133094A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Fap binding molecules and uses thereof
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
WO2023092052A1 (en) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023111153A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized antibodies to human ngf
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US514294A (en) * 1894-02-06 Governor
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
EP0755682A1 (en) * 1991-07-10 1997-01-29 Regeneron Pharmaceuticals, Inc. Methods of treatment of motor neuron diseases using members of the BDNF/NT-3/NGF family of molecules
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AUPR256601A0 (en) * 2001-01-17 2001-02-08 Silverbrook Research Pty. Ltd. An apparatus (AP29)
CA2448956C (en) * 2001-05-30 2017-10-03 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
RU2339647C2 (ru) * 2002-08-19 2008-11-27 Астразенека Аб Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
PL211654B1 (pl) * 2002-10-08 2012-06-29 Rinat Neuroscience Corp Przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego, zastosowanie tego przeciwciała do wytwarzania leku do leczenia bólu pooperacyjnego i kompozycja farmaceutyczna zawierająca przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
SI2263692T1 (sl) * 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
AU2004213044A1 (en) * 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
EP2364728A1 (en) * 2003-07-15 2011-09-14 Amgen, Inc Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
US20090041659A1 (en) * 2003-12-05 2009-02-12 Schreiber John R Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
DK2206728T3 (en) * 2004-04-07 2018-04-23 Rinat Neuroscience Corp METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US9315571B2 (en) * 2005-01-24 2016-04-19 Elan Pharma International Limited Specific binding members for NGF
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US7872102B2 (en) * 2005-08-25 2011-01-18 Eli Lilly And Company Anti-IL-23 antibodies
US9789161B2 (en) * 2006-04-28 2017-10-17 Warsaw Orthopedic, Inc. Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
ME00977B (me) 2007-08-10 2012-06-20 Regeneron Pharma Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta
UY32608A (es) 2009-05-04 2010-12-31 Pangenetics 110 B V Anticuerpos contra el factor de crecimiento nervioso (ngf) con una estabilidad in vivo mejorada

Also Published As

Publication number Publication date
WO2009023540A1 (en) 2009-02-19
KR20100058537A (ko) 2010-06-03
KR101709488B1 (ko) 2017-02-24
BRPI0815370B8 (pt) 2021-05-25
KR20150125735A (ko) 2015-11-09
MY161564A (en) 2017-04-28
KR101709495B1 (ko) 2017-02-23
RU2010108525A (ru) 2011-09-20
MX2010001395A (es) 2010-03-10
ES2517872T3 (es) 2014-11-04
US7988967B2 (en) 2011-08-02
US8613927B2 (en) 2013-12-24
MY153781A (en) 2015-03-13
DOP2010000054A (es) 2010-03-15
CN101827609B (zh) 2014-03-12
EP2187964B1 (en) 2014-10-08
ECSP10010029A (es) 2010-04-30
HRP20141025T1 (hr) 2015-01-02
JP2010535509A (ja) 2010-11-25
HK1144379A1 (en) 2011-02-18
NZ583200A (en) 2012-03-30
TN2010000059A1 (fr) 2011-09-26
US20110256587A1 (en) 2011-10-20
IL203558A (en) 2014-03-31
MA31695B1 (fr) 2010-09-01
BRPI0815370B1 (pt) 2020-10-20
RU2473564C2 (ru) 2013-01-27
ME02239B (me) 2015-04-30
AU2008287037A1 (en) 2009-02-19
CA2695997A1 (en) 2009-02-19
CY1116072T1 (el) 2017-02-08
ZA201000725B (en) 2011-06-29
PL2187964T3 (pl) 2015-03-31
CR11298A (es) 2010-03-23
JP5632744B2 (ja) 2014-11-26
CO6261383A2 (es) 2011-03-22
BRPI0815370A2 (pt) 2015-02-10
PT2187964E (pt) 2015-01-14
EP2572729A2 (en) 2013-03-27
CN101827609A (zh) 2010-09-08
US8148107B2 (en) 2012-04-03
RS53661B1 (en) 2015-04-30
CA2695997C (en) 2016-11-22
US20090041717A1 (en) 2009-02-12
SI2187964T1 (sl) 2015-01-30
US20120164688A1 (en) 2012-06-28
DK2187964T3 (en) 2015-01-12
AU2008287037B2 (en) 2013-10-10
EP2572729A3 (en) 2013-06-05
EP2187964A1 (en) 2010-05-26
NI201000021A (es) 2010-07-27

Similar Documents

Publication Publication Date Title
ME00977B (me) Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta
UA110049C2 (uk) ЛІКУВАННЯ ОСТЕОАРТРИТУ ІМУНОГЛОБУЛІНОВИМ ЗВ'ЯЗУВАЛЬНИМ БІЛКОМ З ПОДВІЙНИМ ВАРІАБЕЛЬНИМ ДОМЕНОМ, ЩО ЗВ'ЯЗУЄ IL-1α І IL-1β
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
RU2016115866A (ru) Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
MX2011000767A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
MX2014003830A (es) Molecula de union al antigeno para promover la perdida de los antigenos.
MY186351A (en) Multispecific antibodies
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
AR069495A1 (es) Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis)
UA109658C2 (xx) Антитіло проти cgrp
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
RS54795B1 (sr) Anti-her3 antitela i njihova korišćenja
UA116614C2 (uk) Антитіло до фактора d і його застосування
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
UA110358C2 (en) Molecules of antibody binding il-17a and il-17f
NZ594682A (en) Fully human antibodies specific to cadm1
MY161295A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
MA32838B1 (fr) Procede de modulation de l'activite antagoniste d'un anticorps monoclonal
PE20110808A1 (es) Anticuerpos contra el receptor 3 de tipo toll
EA201991203A1 (ru) Способы лечения ожирения антителами к angptl8
EA201101303A1 (ru) Молекулы антител, обладающие связывающей специфичностью в отношении il-13 человека